3 Reasons I'm Still Not Buying Tilray Stock -- Even at Penny-Stock Prices

Tilray’s fiscal Q1 2027 revenue rose 23% year over year to a record $257.1 million, but growth was materially aided by its BrewDog asset acquisition; cannabis revenue fell 13% to $56.1 million, and the company reported a $0.32 loss per share versus near break-even a year earlier. The article argues that persistent unprofitability, uncertain cannabis regulation and potential competition mean regulatory progress or even U.S. federal legalization may not deliver a turnaround.

Analysis

The key issue is not headline growth but its quality: acquisition-led beverage expansion can obscure weakening cannabis demand, while a larger distribution business may add revenue without proving better consolidated margins or cash conversion. The market should focus on organic segment trends, adjusted operating performance, and cash flow—not record sales. Verify BrewDog’s contribution to earnings, integration costs, and working-capital needs before treating the acquisition as accretive.

Over the next 1–3 months, regulatory headlines can create sharp upside squeezes in a low-priced, sentiment-sensitive stock without changing the operating outlook. Rescheduling may aid research or medical access but does not itself remove the state-by-state supply-chain constraint. Over 6–18 months, federal legalization could expand the addressable market while also inviting well-capitalized alcohol and tobacco entrants, increasing pressure on pricing and customer acquisition. Legalization is therefore not an automatic margin catalyst for Tilray.

Contrarian angle: the stock’s severe historical decline may already discount substantial failure, so an outright short has asymmetric squeeze and borrow risks around policy headlines. The stronger signal for a durable re-rating would be improving cannabis demand alongside positive cash conversion, not acquisition-driven sales growth. Falsifiers include sustained organic cannabis growth, improving operating results and cash flow, or a regulatory change that enables interstate commerce on workable terms.

Key Decisions for Investors

• Do not add TLRY on consolidated revenue growth alone. Require evidence that cannabis sales stabilize and that acquired beverage revenue contributes to operating performance and cash conversion.
• For bearish exposure, prefer a defined-risk put spread over an unhedged short, and consider entering only when option pricing does not already reflect an elevated policy-event premium. Reassess around regulatory announcements.
• Track quarterly organic segment performance, acquisition-related costs, operating cash flow, and working-capital movements; deterioration in these measures would strengthen the downside case.
• Treat federal policy headlines as volatility catalysts, not proof of improved economics. Revisit the thesis if rules materially enable interstate commerce or Tilray demonstrates sustained organic growth with improving cash generation.